Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioNTech SE stock logo
BNTX
BioNTech
$97.53
-1.0%
$97.48
$76.53
$131.49
$23.45B1.35918,266 shs510,755 shs
Beigene, Ltd. stock logo
ONC
Beigene
$240.41
+0.9%
$240.14
$141.31
$287.88
$23.81B0.35462,101 shs189,191 shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$37.73
+2.1%
$37.53
$29.17
$62.40
$7.03B1.111.51 million shs2.27 million shs
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$18.13
+2.4%
$15.47
$12.47
$22.80
$20.56B0.6210.03 million shs11.47 million shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioNTech SE stock logo
BNTX
BioNTech
-0.13%-3.12%-3.40%-13.53%+1.65%
Beigene, Ltd. stock logo
ONC
Beigene
-1.29%+0.61%-2.69%-7.99%+23,830,999,900.00%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-7.04%-8.65%-4.64%-8.72%-2.58%
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
+4.57%+5.79%+19.09%+5.54%+6.75%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioNTech SE stock logo
BNTX
BioNTech
2.609 of 5 stars
4.42.00.00.03.10.80.0
Beigene, Ltd. stock logo
ONC
Beigene
2.8965 of 5 stars
4.50.00.00.01.81.70.6
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
4.2549 of 5 stars
4.50.00.04.73.62.50.0
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
2.592 of 5 stars
3.63.00.80.02.60.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioNTech SE stock logo
BNTX
BioNTech
2.89
Moderate Buy$141.7345.32% Upside
Beigene, Ltd. stock logo
ONC
Beigene
3.00
Buy$319.0032.69% Upside
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
3.00
Buy$67.0877.80% Upside
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
3.11
Buy$24.5035.14% Upside

Current Analyst Ratings Breakdown

Latest RVMD, BNTX, ONC, and TEVA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/28/2025
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$25.00
5/22/2025
BioNTech SE stock logo
BNTX
BioNTech
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$120.00 ➝ $116.00
5/22/2025
BioNTech SE stock logo
BNTX
BioNTech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$134.00 ➝ $134.00
5/14/2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$73.00 ➝ $72.00
5/14/2025
BioNTech SE stock logo
BNTX
BioNTech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$145.00 ➝ $134.00
5/12/2025
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Overweight$21.00 ➝ $23.00
5/8/2025
Beigene, Ltd. stock logo
ONC
Beigene
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$312.00 ➝ $311.00
5/8/2025
Beigene, Ltd. stock logo
ONC
Beigene
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$348.00 ➝ $350.00
5/8/2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$67.00
5/8/2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$70.00 ➝ $75.00
5/8/2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$87.00 ➝ $80.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioNTech SE stock logo
BNTX
BioNTech
$2.75B8.54$4.19 per share23.25$92.17 per share1.06
Beigene, Ltd. stock logo
ONC
Beigene
$4.18B5.70N/AN/A$37.10 per share6.48
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$742K9,471.55N/AN/A$11.09 per share3.40
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$16.62B1.24$3.59 per share5.05$4.75 per share3.82
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioNTech SE stock logo
BNTX
BioNTech
$1.01B-$3.40N/AN/AN/A-15.16%-2.35%-2.05%8/4/2025 (Estimated)
Beigene, Ltd. stock logo
ONC
Beigene
-$881.71M-$3.72N/A338.617.73-25.94%-25.12%-14.95%N/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$436.37M-$4.00N/AN/AN/AN/A-33.67%-30.08%8/6/2025 (Estimated)
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
-$1.64B-$1.15N/A6.891.44-9.91%42.46%6.65%7/30/2025 (Estimated)

Latest RVMD, BNTX, ONC, and TEVA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2025Q1 2025
Beigene, Ltd. stock logo
ONC
Beigene
-$0.71$1.22+$1.93$0.01$1.12 billion$1.12 billion
5/7/2025Q1 2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$1.12-$1.13-$0.01-$1.13N/AN/A
5/7/2025Q1 2025
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$0.47$0.52+$0.05$0.18$3.99 billion$3.89 billion
3/10/2025Q4 2024
BioNTech SE stock logo
BNTX
BioNTech
$0.38$1.08+$0.70$1.15$1.24 billion$1.19 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioNTech SE stock logo
BNTX
BioNTech
$1.531.57%N/AN/A N/A
Beigene, Ltd. stock logo
ONC
Beigene
N/AN/AN/AN/AN/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
N/AN/AN/AN/AN/A
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$1.015.58%N/AN/A N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioNTech SE stock logo
BNTX
BioNTech
0.01
7.33
7.21
Beigene, Ltd. stock logo
ONC
Beigene
0.05
1.93
1.72
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
N/A
14.24
14.24
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
2.97
0.98
0.75

Institutional Ownership

CompanyInstitutional Ownership
BioNTech SE stock logo
BNTX
BioNTech
15.52%
Beigene, Ltd. stock logo
ONC
Beigene
48.55%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
94.34%
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
54.05%

Insider Ownership

CompanyInsider Ownership
BioNTech SE stock logo
BNTX
BioNTech
19.20%
Beigene, Ltd. stock logo
ONC
Beigene
6.62%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
8.20%
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
0.55%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioNTech SE stock logo
BNTX
BioNTech
3,080240.39 million193.71 millionOptionable
Beigene, Ltd. stock logo
ONC
Beigene
9,00099.05 million90.59 millionN/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
250186.27 million154.76 millionOptionable
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
36,8001.13 billion1.13 billionOptionable

Recent News About These Companies

FDA fast-tracks Teva's coeliac disease treatment
Teva initiated with bullish view at Truist, here's why
Why Is Teva Stock Trading Higher On Tuesday?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
BioNTech stock logo

BioNTech NASDAQ:BNTX

$97.53 -1.02 (-1.04%)
Closing price 04:00 PM Eastern
Extended Trading
$97.00 -0.53 (-0.54%)
As of 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Beigene stock logo

Beigene NASDAQ:ONC

$240.41 +2.10 (+0.88%)
As of 04:00 PM Eastern

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.

Revolution Medicines stock logo

Revolution Medicines NASDAQ:RVMD

$37.73 +0.76 (+2.06%)
Closing price 04:00 PM Eastern
Extended Trading
$37.40 -0.33 (-0.89%)
As of 07:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Teva Pharmaceutical Industries stock logo

Teva Pharmaceutical Industries NYSE:TEVA

$18.13 +0.42 (+2.37%)
Closing price 03:59 PM Eastern
Extended Trading
$18.23 +0.10 (+0.52%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.